Welcome to our dedicated page for KEWAUNEE SCIENTIFIC /DE/ SEC filings (Ticker: KEQU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on KEWAUNEE SCIENTIFIC /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into KEWAUNEE SCIENTIFIC /DE/'s regulatory disclosures and financial reporting.
HULL THOMAS DAVID III reported acquisition or exercise transactions in this Form 4 filing.
KEWAUNEE SCIENTIFIC CORP President & CEO Thomas David Hull III reported an equity compensation grant in the form of restricted stock units. He received 15,195 RSUs tied to the company’s common stock, each representing a contingent right to one share, with no cash paid per unit.
The RSUs will vest in three equal annual installments starting on June 30, 2027, as long as he remains employed by the company. Following this award, his reported holdings for this RSU grant total 15,195 units directly.
Kewaunee Scientific Corporation reported fiscal year 2026 sales of $281,999,000, up 17.3% from the prior year, reflecting growth in both its Lab Products Group and International segments. Full-year net earnings were $9,618,000, with diluted EPS of $3.22, compared to $3.83 a year earlier.
EBITDA for the year was $22,425,000, slightly above the prior year, while adjusted EBITDA reached $23,210,000 after excluding Nu Aire integration costs. The company reduced long-term debt to $40,851,000 and improved its debt-to-equity ratio to 0.61-to-1, ending the year with order backlog of $165.9 million. Fourth-quarter sales were $71,400,000, with net earnings of $3,388,000 and diluted EPS of $1.13.
Kewaunee Scientific Corporation filed a current report stating it will release financial results for its fourth quarter and fiscal year ended April 30, 2026 on June 23, 2026 after the close of trading. The results will be posted on the company’s website.
The filing also highlights Kewaunee’s global business in laboratory, healthcare, and technical furniture, and notes its newly acquired subsidiary Nu Aire, a manufacturer of biological safety cabinets and other laboratory equipment. The press release includes standard forward-looking statement language outlining various business risks and uncertainties.
Campbell John Jette reported acquisition or exercise transactions in this Form 4 filing.
Kewaunee Scientific director John Jette Campbell received an equity grant of 2,013 shares of Common Stock as part of his annual compensation. The shares were awarded at no cash cost under the company’s 2023 Omnibus Incentive Plan, increasing his directly held position to 2,703 shares after the award.
GEHL KEITH M reported acquisition or exercise transactions in this Form 4 filing.
Kewaunee Scientific director Keith M. Gehl received a grant of 2,013 shares of Common Stock on May 1, 2026. The shares were awarded under the company’s 2023 Omnibus Incentive Plan as the equity portion of his annual compensation and were granted at $0.00 per share. Following this award, he directly holds 22,409 shares of Kewaunee Scientific common stock.
Kewaunee Scientific director Margaret B. Pyle reported a bona fide gift of 2,750 shares of common stock held indirectly through a trust. The shares were transferred on March 26, 2026, as a gift to five grandchildren, with no sale proceeds involved. After the transfer, trust-related indirect holdings reported for her total 36,891 shares, and a separate 5,000 shares are reported as held indirectly by her spouse.
Kewaunee Scientific Corporation reported quarterly net sales of $69,399,000, slightly above $67,167,000 a year ago, and nine‑month net sales of $210,599,000 versus $163,324,000, reflecting growth helped by the Nu Aire acquisition. Nine‑month gross profit was $59,195,000, with gross margin improving to 28.1% of sales from 27.4%.
Net earnings attributable to Kewaunee Scientific Corporation for the nine months were $6,230,000, down from $6,555,000, with diluted earnings per share of $2.09 compared to $2.20. Order backlog was $183.2 million at January 31, 2026, below $221.6 million a year earlier and $214.6 million at April 30, 2025.
Operating activities generated $13,173,000 of cash, up from $5,376,000, while cash, cash equivalents and restricted cash decreased to $10,347,000 from $17,164,000. The company refinanced its Nu Aire seller notes, repaying $23,000,000 of principal and related interest, and ended the period with total long‑term debt of $21,333,000 versus $37,685,000, remaining in compliance with loan covenants.
Kewaunee Scientific Corporation reported mixed results for its third quarter ended January 31, 2026. Sales were $69.4 million, up 3.3% from $67.2 million a year earlier, and consolidated EBITDA was $3.8 million, slightly above $3.7 million.
Despite higher sales, net earnings attributable to Kewaunee fell to $0.7 million, down from $1.4 million, with diluted EPS declining to $0.23 from $0.45. Domestic sales decreased 2.0%, while international sales grew 21.4%, lifting international segment EBITDA to $2.0 million from $0.8 million.
The order backlog was $183.2 million versus $221.6 million a year earlier, reflecting softer construction-related activity. The company reduced long-term debt from $60.7 million on April 30, 2025, to $42.3 million, improving its debt-to-equity ratio to 0.68-to-1 from 0.99-to-1 as it continues integrating the Nu Aire acquisition and investing in its corporate platform.
Kewaunee Scientific Corporation announced that it plans to release its third quarter fiscal year 2026 financial results on March 11, 2026, after the close of trading. The results will be posted on the company’s website.
The company describes itself as a global provider of laboratory, healthcare, and technical furniture and related equipment, and notes that its portfolio now includes products from its newly acquired subsidiary, Nu Aire.
Northern Trust Corporation reported beneficial ownership of 252,328 shares of Kewaunee Scientific common stock, representing 8.8% of the outstanding class as of 12/31/2025. Northern Trust has sole voting and dispositive power over 15,967 shares and shared power over 236,361 shares.
The shares were acquired and are held in the ordinary course of business, and Northern Trust certifies they are not held for the purpose or effect of changing or influencing control of Kewaunee Scientific.